GeneDx Holdings (WGS) Research & Development (2020 - 2026)

GeneDx Holdings has disclosed Research & Development across 7 years of filings, most recently posting $19.8 million for Q1 2026.

• In Q1 2026, Research & Development rose 57.46% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $79.3 million (up 69.59% YoY), while the FY2025 annual figure was $72.0 million, up 57.53% from the prior year.
• Research & Development fell to $19.8 million in Q1 2026, from $24.5 million in the prior quarter.
• Over the last five years, Research & Development for WGS reached as high as $27.2 million in Q2 2022 and fell as low as $10.9 million in Q2 2024.
• The 5-year median for Research & Development is $14.6 million (2023), against an average of $16.6 million.
• The widest YoY moves for Research & Development: up 127.31% in 2022, down 59.88% in 2022.
• A 5-year view of Research & Development shows it stood at $24.4 million in 2022, then tumbled by 49.73% to $12.2 million in 2023, then fell by 5.39% to $11.6 million in 2024, then surged by 111.78% to $24.5 million in 2025, then declined by 19.3% to $19.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $19.8 million, $24.5 million, and $19.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.